奥马珠单抗联合布地奈德治疗重度支气管哮喘患儿的效果  

Effect of omalizumab combined with budesonide in the treatment of children with severe bronchial asthma

作　　者：张小宁 张向峰 张志英[1] ZHANG Xiaoning;ZHANG Xiangfeng;ZHANG Zhiying(Department of Respiratory,Children's Hospital Affiliated to Zhengzhou University,Henan Children's Hospital,Zhengzhou Children's Hospital,Zhengzhou 450003,China)

机构地区：[1]郑州大学附属儿童医院,河南省儿童医院,郑州儿童医院,呼吸科,郑州450003

出　　处：《西北药学杂志》2022年第2期117-121,共5页Northwest Pharmaceutical Journal

基　　金：河南省医学科技攻关计划项目(编号:LHGJ20190938)。

摘　　要：目的探究奥马珠单抗联合布地奈德雾化吸入治疗重度支气管哮喘患儿的影响。方法选取重度支气管哮喘患儿114例,按照随机数字表法分为观察组(55例)和对照组(59例),对照组采用糖皮质激素雾化吸入治疗,观察组在对照组治疗的基础上联合奥马珠单抗治疗。治疗6个月,观察2组的临床疗效、肺功能、外周血嗜酸性粒细胞(EOS)、免疫球蛋白E(IgE)、免疫球蛋白T细胞、哮喘控制评分、哮喘生活质量评分和不良反应。结果与对照组比较,观察组治疗后总有效率较高(94.55%vs.81.36%,P<0.05);观察组治疗后第一秒用力呼气容积(FEV_(1))、用力呼气肺活量(FVC)和FEV_(1)/FVC均高于对照组(P<0.05);观察组治疗后EOS和IgE低于对照组(P<0.05);观察组治疗后辅助性T细胞2(Th2)和辅助性T细胞17(Th17)均低于对照组(P<0.05);观察组治疗后哮喘控制评分和哮喘生活质量评分均高于对照组(P<0.05);2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论奥马珠单抗联合布地奈德雾化吸入治疗重度支气管哮喘患儿,可明显改善肺功能,降低EOS和IgE水平,控制气道炎症,治疗效果较好。Objective To explore the effect of omalizumab combined with budesonide in the treatment of children with severe bronchial asthma.Methods A total of 114 children with severe bronchial asthma were selected.According to the random number table method,they were divided into observation group(55 cases)and control group(59 cases).The control group were treated with nebulized corticosteroid,and the observation group were supplemented with omalizumab.After 6 months of treatment,the clinical efficacy,lung function,percentage of eosinophils in peripheral blood(EOS),immunoglobulin E(IgE),T cells,asthma control score,asthma quality of life score,and adverse reactions were observed and compared.Results The total effective rate of the observation group after treatment was higher than that of the control group(94.55%vs.81.36%,P<0.05).The forced expiratory volume in 1 second(FEV_(1)),the forced expiratory vital capacity(FVC),and the 1 second rate of forced expiratory vital capacity(FEV_(1)/FVC)in the observation group were higher than those in the control group(P<0.05).The EOS and IgE in the observation group were lower than those in the control group(P<0.05).Th2 and Th17 in the observation group were lower than those in the control group(P<0.05).The asthma control score and the asthma quality of life score after treatment were higher in observation group than in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Omalizumab combined with nebulized glucocorticoid can significantly improve the lung function,reduce the EOS and IgE,and control airway inflammation in children with severe bronchial asthma with good efficacy.

关 键 词：奥马珠单抗 布地奈德 支气管哮喘 肺功能 外周血嗜酸性粒细胞 T细胞 

分 类 号：R985[医药卫生—药品]